Area of research
Cardiology and Cardiovascular Medicine · Pulmonary and Respiratory Medicine
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Cardiac pacing and defibrillation studies, and Electrolyte and hormonal disorders.
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease
Medication Dosing for Heart Failure with Reduced Ejection Fraction — Opportunities and Challenges
Mode of Death in Heart Failure With Preserved Ejection Fraction
Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction
Patient-Reported Outcomes in the Soluble Guanylate Cyclase Stimulator in Heart Failure Patients with Preserved Ejection Fraction (SOCRATES-PRESERVED) Study
Renin–Angiotensin Blockade in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure
Mitochondrial function as a therapeutic target in heart failure
Cancer Therapy–Related Cardiac Dysfunction and Heart Failure
Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction
Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage
Population Risk Prediction Models for Incident Heart Failure
Rationale and Design of a Randomized, Double-Blind, Event-Driven, Multicentre Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Exacerbation of Heart Failure: The COMMANDER HF Trial
In-Hospital Worsening Heart Failure
Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy
Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial)
Acute Heart Failure: The Role of Focused Emergency Cardiopulmonary Ultrasound in Identification and Early Management
Agents with Vasodilator Properties in Acute Heart Failure: How to Design Successful Trials
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Developing Therapies for Heart Failure With Preserved Ejection Fraction
Decongestion in Acute Heart Failure
Rationale and Design of The SOluble guanylate Cyclase StimulatoR in HeArT FailurE Studies (SOCRATES)
Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial)
Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials
Molecular and Cellular Basis of Viable Dysfunctional Myocardium
Management of Comorbid Diabetes Mellitus and Worsening Heart Failure
Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes
Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries